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Summary
This report updates U.S. Public Health Service recommendations for the management of health-care personnel (HCP) who
have occupational exposure to blood and other body fluids that might contain human immunodeficiency virus (HIV). Although
the principles of exposure management remain unchanged, recommended HIV postexposure prophylaxis (PEP) regimens have
been changed. This report emphasizes adherence to HIV PEP when it is indicated for an exposure, expert consultation in manage-
ment of exposures, follow-up of exposed workers to improve adherence to PEP, and monitoring for adverse events, including
seroconversion. To ensure timely postexposure management and administration of HIV PEP, clinicians should consider occupa-
tional exposures as urgent medical concerns.
On the basis of this discussion, the PHS working group
decided that updated recommendations for the management
of occupational exposure to HIV were warranted.
This report modifies and expands the list of antiretroviral
medications that can be considered for use as PEP. This report
also emphasizes prompt management of occupational expo-
sures, selection of tolerable regimens, attention to potential
drug interactions involving drugs that could be included in
HIV PEP regimens and other medications, consultation with
experts for postexposure management strategies (especially
determining whether an exposure has actually occurred) and
selection of HIV PEP regimens, use of HIV rapid testing, and
counseling and follow-up of exposed personnel.
Recommendations on the management of occupational
exposures to hepatitis B virus or hepatitis C virus have been
published previously (3) and are not included in this report.
Recommendations for nonoccupational (e.g., sexual, pediat-
ric, and perinatal) HIV exposures also have been published
previously (4–6).
Definition of Health-Care Personnel
and Exposure
The definitions of health-care personnel (HCP) and occu-
pational exposures are unchanged from those used in 2001
(3). The term HCP refers to all paid and unpaid persons work-
ing in health-care settings who have the potential for expo-
sure to infectious materials (e.g., blood, tissue, and specific
body fluids and medical supplies, equipment, or environmental
Introduction
Although preventing exposures to blood and body fluids is
the primary means of preventing occupationally acquired
human immunodeficiency virus (HIV) infection, appropri-
ate postexposure management is an important element of
workplace safety. In 1996, the first U.S. Public Health Service
(PHS) recommendations for the use of postexposure prophy-
laxis (PEP) after occupational exposure to HIV were published;
these recommendations have been updated twice (1–3). Since
publication of the most recent guidelines in 2001, new
antiretroviral agents have been approved by the Food and Drug
Administration (FDA), and additional information has
become available regarding the use and safety of HIV PEP. In
August 2003, CDC convened a meeting of a PHS interagency
working group* and consultants to assess use of HIV PEP.
* This interagency working group included representatives from CDC, FDA,
the Health Resources and Services Administration, and the National Institutes
of Health. Information included in these recommendations might not
represent FDA approval or approved labeling for the particular product or
indications in question. Specifically, the terms “safe” and “effective” might
not be synonymous with the FDA-defined legal standard for product approval.
The material in this report originated in the National Center for
Infectious Diseases, Anne Schuchat, MD, Acting Director; Division
of Healthcare Quality Promotion, Denise M. Cardo, MD, Director.
Corresponding preparer: Adelisa L. Panlilio, MD, MPH, Division
of Healthcare Quality Promotion, National Center for Infectious
Diseases, CDC, 1600 Clifton Rd., NE, MS E-68, Atlanta, GA 30333.
Telephone: 404-498-1265; Fax: 404-498-1244; E-mail: alp4@cdc.gov.
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surfaces contaminated with these substances). HCP might
include, but are not limited to, emergency medical service
personnel, dental personnel, laboratory personnel, autopsy
personnel, nurses, nursing assistants, physicians, technicians,
therapists, pharmacists, students and trainees, contractual staff
not employed by the health-care facility, and persons not
directly involved in patient care but potentially exposed to
blood and body fluids (e.g., clerical, dietary, housekeeping,
maintenance, and volunteer personnel). The same principles
of exposure management could be applied to other workers
who have potential for occupational exposure to blood and
body fluids in other settings.
An exposure that might place HCP at risk for HIV infec-
tion is defined as a percutaneous injury (e.g., a needlestick or
cut with a sharp object) or contact of mucous membrane or
nonintact skin (e.g., exposed skin that is chapped, abraded,
or afflicted with dermatitis) with blood, tissue, or other body
fluids that are potentially infectious. In addition to blood and
visibly bloody body fluids, semen and vaginal secretions also
are considered potentially infectious. Although semen and
vaginal secretions have been implicated in the sexual trans-
mission of HIV, they have not been implicated in occupa-
tional transmission from patients to HCP. The following fluids
also are considered potentially infectious: cerebrospinal fluid,
synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid,
and amniotic fluid. The risk for transmission of HIV infec-
tion from these fluids is unknown; the potential risk to HCP
from occupational exposures has not been assessed by epide-
miologic studies in health-care settings. Feces, nasal secretions,
saliva, sputum, sweat, tears, urine, and vomitus are not con-
sidered potentially infectious unless they are visibly bloody;
the risk for transmission of HIV infection from these fluids
and materials is low (7).
Any direct contact (i.e., contact without barrier protection)
to concentrated virus in a research laboratory or production
facility requires clinical evaluation. For human bites, clinical
evaluation must include the possibility that both the person
bitten and the person who inflicted the bite were exposed to
bloodborne pathogens. Transmission of HIV infection by this
route has been reported rarely, but not after an occupational
exposure (8–12).
Risk for Occupational Transmission
of HIV
 The risks for occupational transmission of HIV have been
described; risks vary with the type and severity of exposure
(2,3,7). In prospective studies of HCP, the average risk for
HIV transmission after a percutaneous exposure to HIV-
infected blood has been estimated to be approximately 0.3%
(95% confidence interval [CI] = 0.2%–0.5%) (7) and after
a mucous membrane exposure, approximately 0.09%
(CI = 0.006%–0.5%) (3). Although episodes of HIV trans-
mission after nonintact skin exposure have been documented,
the average risk for transmission by this route has not been
precisely quantified but is estimated to be less than the risk
for mucous membrane exposures. The risk for transmission
after exposure to fluids or tissues other than HIV-infected
blood also has not been quantified but is probably consider-
ably lower than for blood exposures.
Epidemiologic and laboratory studies suggest that multiple
factors might affect the risk for HIV transmission after an
occupational exposure (3). In a retrospective case-control study
of HCP who had percutaneous exposure to HIV, increased
risk for HIV infection was associated with exposure to a larger
quantity of blood from the source person as indicated by 1) a
device (e.g., a needle) visibly contaminated with the patient’s
blood, 2) a procedure that involved a needle being placed
directly in a vein or artery, or 3) a deep injury. The risk also
was increased for exposure to blood from source persons with
terminal illness, possibly reflecting either the higher titer of
HIV in blood late in the course of acquired immunodeficiency
syndrome (AIDS) or other factors (e.g., the presence of syn-
cytia-inducing strains of HIV). A laboratory study that dem-
onstrated that more blood is transferred by deeper injuries
and hollow-bore needles lends further support for the observed
variation in risk related to blood quantity (3).
The use of source-person viral load as a surrogate measure
of viral titer for assessing transmission risk has not yet been
established. Plasma viral load (e.g., HIV RNA) reflects only
the level of cell-free virus in the peripheral blood; latently
infected cells might transmit infection in the absence of vire-
mia. Although a lower viral load (e.g., <1,500 RNA copies/
mL) or one that is below the limits of detection probably
indicates a lower titer exposure, it does not rule out the possi-
bility of transmission.
Antiretroviral Agents for PEP
Antiretroviral agents from five classes of drugs are currently
available to treat HIV infection (13,14). These include the
nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide
reverse transcriptase inhibitors (NtRTIs), nonnucleoside re-
verse transcriptase inhibitors (NNRTIs), protease inhibitors
(PIs), and a single fusion inhibitor. Only antiretroviral agents
approved by FDA for treatment of HIV infection are included
in these guidelines. The recommendations in this report pro-
vide guidance for two- or-more drug PEP regimens on the
basis of the level of risk for HIV transmission represented by
the exposure (Tables 1 and 2; Appendix).






















































TABLE 1. Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries
Infection status of source
* HIV-positive, class 1 — asymptomatic HIV infection or known low viral load (e.g., <1,500 ribonucleic acid copies/mL). HIV-positive, class 2 — symptomatic
HIV infection, acquired immunodeficiency syndrome, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert consul-
tation. Initiation of PEP should not be delayed pending expert consultation, and, because expert consultation alone cannot substitute for face-to-face
counseling, resources should be available to provide immediate evaluation and follow-up care for all exposures.
† For example, deceased source person with no samples available for HIV testing.
§ For example, a needle from a sharps disposal container.
¶ For example, solid needle or superficial injury.
** The recommendation “consider PEP” indicates that PEP is optional; a decision to initiate PEP should be based on a discussion between the exposed
person and the treating clinician regarding the risks versus benefits of PEP.
†† If PEP is offered and administered and the source is later determined to be HIV-negative, PEP should be discontinued.











































Infection status of source
TABLE 2. Recommended HIV postexposure prophylaxis (PEP) for mucous membrane exposures and nonintact skin* exposures
* For skin exposures, follow-up is indicated only if evidence exists of compromised skin integrity (e.g., dermatitis, abrasion, or open wound).
† HIV-positive, class 1 — asymptomatic HIV infection or known low viral load (e.g., <1,500 ribonucleic acid copies/mL). HIV-positive, class 2 — symptomatic
HIV infection, AIDS, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert consultation. Initiation of PEP should not
be delayed pending expert consultation, and, because expert consultation alone cannot substitute for face-to-face counseling, resources should be avail-
able to provide immediate evaluation and follow-up care for all exposures.
§ For example, deceased source person with no samples available for HIV testing.
¶ For example, splash from inappropriately disposed blood.
** For example, a few drops.
†† The recommendation “consider PEP” indicates that PEP is optional; a decision to initiate PEP should be based on a discussion between the exposed
person and the treating clinician regarding the risks versus benefits of PEP.
§§ If PEP is offered and administered and the source is later determined to be HIV-negative, PEP should be discontinued.
¶¶ For example, a major blood splash.
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Toxicity and Drug Interactions of
Antiretroviral Agents
Persons receiving PEP should complete a full 4-week regi-
men (3). However, as a result of toxicity and side effects among
HCP, a substantial proportion of HCP have been unable to
complete a full 4-week course of HIV PEP (15–20). Because
all antiretroviral agents have been associated with side effects
(Table 3), the toxicity profile of these agents, including the
frequency, severity, duration, and reversibility of side effects,
is an important consideration in selection of an HIV PEP
regimen. The majority of data concerning adverse events have
been reported primarily for persons with established HIV
infection receiving prolonged antiretroviral therapy and there-
fore might not reflect the experience of uninfected persons
who take PEP. Anecdotal evidence from clinicians knowledge-
able about HIV treatment indicates that antiretroviral agents
are tolerated more poorly among HCP taking HIV PEP than
among HIV-infected patients on antiretroviral medications.
Side effects have been reported frequently by persons tak-
ing antiretroviral agents as PEP (15–23). In multiple instances,
a substantial (range: 17%–47%) proportion of HCP taking
PEP after occupational exposures to HIV-positive sources did
not complete a full 4-week course of therapy because of in-
ability to tolerate the drugs (15–17,19,20). Data from the
National Surveillance System for Health Care Workers
(NaSH), CDC’s occupational surveillance system for occupa-
tional exposures and infections in hospitals, for June 1995–
December 2004 indicate that 401 (46.9%) of 921 HCP with
at least one follow-up visit after starting PEP experienced one
or more symptoms. The symptom reported most frequently
was nausea (26.5%), followed by malaise and fatigue (22.8%)
(CDC, unpublished data, 2005). Of 503 HCP who stopped
HIV PEP prematurely (<28 days), 361 (24.0%) did so
because of adverse effects of the drugs. Similar data have been
reported from the Italian Registry of Antiretroviral
Postexposure Prophylaxis, which includes data primarily on
HCP taking PEP but also collects data on those taking PEP
after nonoccupational exposures (18). In multivariate analy-
sis, those taking regimens that include PI were more likely to
experience PEP-associated side effects and to discontinue PEP
prematurely (<28 days). Because side effects are frequent and
TABLE 3. Primary side effects and toxicities associated with antiretroviral agents used for HIV postexposure prophylaxis, by
class and agent
Class and agent Side effect and toxicity
Nucleoside reverse transcriptase inhibitors Class warning: all NRTIs have the potential to cause lactic acidosis with hepatic steatosis
(NRTI)
Zidovudine (Retrovir®; ZDV, AZT) Anemia, neutropenia, nausea, headache, insomnia, muscle pain, and weakness
Lamivudine (Epivir®, 3TC) Abdominal pain, nausea, diarrhea, rash, and pancreatitis
Stavudine (Zerit™; d4T) Peripheral neuropathy, headache, diarrhea, nausea, insomnia, anorexia, pancreatitis, elevated liver
function tests (LFTs), anemia, and neutropenia
Didanosine (Videx®; ddI) Pancreatitis, lactic acidosis, neuropathy, diarrhea, abdominal pain, and nausea
Emtricitabine (Emtriva, FTC) Headache, nausea, vomiting, diarrhea, and rash. Skin discoloration (mild hyperpigmentation on palms
and soles), primarily among nonwhites
Nucleotide analogue reverse transcriptase Class warning: All NtRTIs have the potential to cause lactic acidosis with hepatic steatosis
inhibitor (NtRTI)
Tenofovir (Viread®; TDF) Nausea, diarrhea, vomiting, flatulence, and headache
Nonnucleoside reverse transcriptase inhibitors
(NNRTIs)
Efavirenz (Sustiva®; EFV) Rash (including cases of Stevens-Johnson syndrome), insomnia, somnolence, dizziness, trouble
concentrating,  abnormal dreaming, and teratogenicity
Protease inhibitor
Indinavir (Crixivan®; IDV) Nausea, abdominal pain, nephrolithiasis, and indirect hyperbilirubinemia
Nelfinavir (Viracept®; NFV) Diarrhea, nausea, abdominal pain, weakness, and rash
Ritonavir (Norvir®; RTV) Weakness, diarrhea, nausea, circumoral paresthesia, taste alteration, and elevated cholesterol and
triglycerides
Saquinavir (Invirase®; SQV) Diarrhea, abdominal pain, nausea, hyperglycemia, and elevated LFTs
Fosamprenavir (Lexiva®, FOSAPV) Nausea, diarrhea, rash, circumoral paresthesia, taste alteration, and depression
Atazanavir (Reyataz®; ATV) Nausea, headache, rash, abdominal pain, diarrhea, vomiting, and indirect hyperbilirubinemia
Lopinavir/ritonavir (Kaletra®; LPV/RTV) Diarrhea, fatigue, headache, nausea, and increased cholesterol and triglycerides
Fusion inhibitor
Enfuvirtide (Fuzeon®; T-20) Local injection site reactions, bacterial pneumonia, insomnia, depression, peripheral neuropathy, and
cough
Sources: Package inserts; Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and
adolescents—April 7, 2005. Washington, DC: National Institutes of Health; 2005. Available at http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50.
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particularly because they are cited as a major reason for not
completing PEP regimens as prescribed, the selection of regi-
mens should be heavily influenced toward those that are tol-
erable for short-term use.
In addition, all approved antiretroviral agents might have
potentially serious drug interactions when used with certain
other drugs, requiring careful evaluation of concomitant medi-
cations, including over-the-counter medications and supple-
ments (e.g., herbals), used by an exposed person before
prescribing PEP and close monitoring for toxicity of anyone
receiving these drugs (24–33) (Tables 3–5). PIs and NNRTIs
have the greatest potential for interactions with other drugs.
Information regarding potential drug interactions has been
published (13,24–33). Additional information is included in
the manufacturers’ package inserts. Because of interactions,
certain drugs should not be administered concomitantly with
PIs or with efavirenz (EFV) (Tables 4 and 5). Consultation
with a pharmacist might be considered.
Selection of HIV PEP Regimens
Determining which agents and how many to use or when
to alter a PEP regimen is primarily empiric (34). Guidelines
for treating HIV infection, a condition typically involving a
high total body burden of HIV, recommend use of three or
more drugs (13,14); however, the applicability of these rec-
ommendations to PEP is unknown. Among HIV-infected
patients, combination regimens with three or more
antiretroviral agents have proved superior to monotherapy and
dual-therapy regimens in reducing HIV viral load, reducing
incidence of opportunistic infections and death, and delaying
onset of drug resistance (13,14). In theory, a combination of
drugs with activity at different stages in the viral replication
cycle (e.g., nucleoside analogues with a PI) might offer an
additive preventive effect in PEP, particularly for occupational
exposures that pose an increased risk for transmission or for
transmission of a resistant virus. Although use of a three- (or
more) drug regimen might be justified for exposures that pose
an increased risk for transmission, whether the potential added
toxicity of a third or fourth drug is justified for lower-risk
exposures is uncertain, especially in the absence of data sup-
porting increased efficacy of more drugs in the context of
occupational PEP. Offering a two-drug regimen is a viable
option, primarily because the benefit of completing a full
course of this regimen exceeds the benefit of adding the third
agent and risking noncompletion (35). In addition, the total
body burden of HIV is substantially lower among exposed
HCP than among persons with established HIV infection.
For these reasons, the recommendations in this report pro-
vide guidance for two- and three- (or more) drug PEP regi-
mens on the basis of the level of risk for HIV transmission
represented by the exposure (Tables 1 and 2; Appendix).
Resistance to Antiretroviral Agents
Known or suspected resistance of the source virus to
antiretroviral agents, particularly those that might be included
in a PEP regimen, is a concern for persons making decisions
about PEP (36). Drug resistance to all available antiretroviral
agents has been reported, and cross-resistance within drug
classes is frequent (37). Although occupational transmission
of drug-resistant HIV strains has been reported despite PEP
TABLE 4. Prescription and over-the-counter drugs that should not be administered with protease inhibitors (PIs) because of
drug interactions*
Drug Comment
Antimycobacterials: rifampin Decreases plasma concentrations and area under plasma concentration curve of the majority of PIs
by approximately 90%, which might result in loss of therapeutic effect and development of resistance
Benzodiazepines: midazolam, triazolam Contraindicated because of potential for serious or life-threatening events (e.g., prolonged or increased
sedation or respiratory depression)
Ergot derivatives: dihydroergotamine, Contraindicated because of potential for serious or life-threatening events (e.g., acute ergot toxicity
ergotamine, ergonovine, methylergonovine characterized by peripheral vasospasm and ischemia of the extremities and other tissues)
Gastrointestinal motility agent: cisapride Contraindicated because of potential for serious or life-threatening events (e.g., cardiac arrhythmias)
HMG-CoA reductase inhibitors (“statins”): Potential for serious reactions (e.g., myopathy, including rhabdomyolysis); atorvastatin may be used
lovastatin, simvastatin cautiously, beginning with lowest possible starting dose, and monitoring for adverse events
Neuroleptic: pimozide Contraindicated because of potential for serious or life-threatening events (e.g., cardiac arrhythmias)
Inhaled steroids: fluticasone Coadministration of fluticasone and ritonavir-boosted protease inhibitors are not recommended unless the
potential benefit to the patient outweighs the risk for systemic corticosteroid side effect
Herbal products: Coadministration might reduce plasma concentrations of protease inhibitors,
St. John’s wort (hypericum perforatum), which might result in loss of therapeutic effect and development of resistance
garlic Garlic might lower saquinavir level
* This table does not list all products that should not be administered with PIs (atazanavir, lopinavir/ritonavir, fosamprenavir, indinavir, nelfinavir, saquinavir).
Product labels should be consulted for additional information regarding drug interactions.
Sources: US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington,
DC: US Department of Health and Human Services; 2005. Available at http://www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf; University of California
at San Francisco Center for HIV Information. Database of antiretroviral drug interactions. Available at http://hivinsite.ucsf.edu/InSite?page=ar-00-02.
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with combination drug regimens (36,38–40), the effect of
exposure to a resistant virus on transmission and transmissi-
bility is not well understood.
Since publication of the previous guidelines, an additional
report of an occupational HIV seroconversion despite combi-
nation HIV PEP has been published (Table 6) (38), bringing
the total number of reports worldwide to six. The exposure
was a percutaneous injury sustained by a nurse performing a
phlebotomy on a heavily treatment-experienced patient. At
the time of the exposure, the source patient was failing treat-
ment with stavudine (d4T), lamivudine (3TC), ritonavir
(RTV), and saquinavir (SQV) and had a history of previous
treatment with zidovudine (ZDV) and zalcitabine (ddC).
Genotypic resistance testing performed within 1 month of
the exposure suggested resistance to ZDV and 3TC. Pheno-
typic testing confirmed resistance to 3TC but demonstrated
relative susceptibility to ZDV and d4T. The source virus dem-
onstrated no evidence of resistance to nevirapine (NVP) or
other NNRTIs. The initial HIV PEP regimen started within
95 minutes of the exposure was ZDV, 3TC, and indinavir.
TABLE 5. Prescription and over-the-counter drugs that should not be administered with efavirenz because of drug interactions*
Drug Comment
Antifungal: voriconazole Contraindicated because efavirenz substantially decreases voriconazole plasma concentrations
Benzodiazepines: midazolam, triazolam Contraindicated because of potential for serious or life-threatening events (e.g., prolonged or increased
sedation or respiratory depression)
Ergot derivatives: dihydroergotamine, Contraindicated because of potential for serious or life-threatening events (e.g., acute ergot toxicity
ergotamine, ergonovine, methylergonovine characterized by peripheral vasospasm and ischemia of the extremities and other tissues)
Gastrointestinal motility agent: cisapride Contraindicated because of potential for serious or life-threatening events (e.g., cardiac arrhythmias)
Herbal products: Coadministration might reduce plasma concentrations of protease inhibitors, which might result in loss of
St. John’s wort (hypericum perforatum), therapeutic effect and development of resistance
garlic Garlic might lower saquinavir levels
* This table does not list all products that should not be coadministered with efavirenz. Efavirenz product labeling should be consulted for additional information
regarding drug interactions.
Sources: US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington,
DC: US Department of Health and Human Services; 2005. Available at http://www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf; University of California
at San Francisco Center for HIV Information. Database of antiretroviral drug interactions. Available at http://hivinsite.ucsf.edu/InSite?page=ar-00-02.
TABLE 6. Reported instances of failure of combination drug postexposure prophylaxis (PEP) to prevent HIV-infection among
health-care personnel exposed to HIV-infected blood through percutaneous injury
No. of
Time days to Source-patient
to first onset of No. of days On Virus
Year of dose retroviral to document HIV-infection anti resistant to
incident Device  PEP regimen* (hrs) illness seroconversion† status retrovirals antiretrovirals§
1992¶ Biopsy needle ZDV, ddI 0.5 23 23 AIDS, terminally ill Yes Unknown
1996** Hollow-bore needle ZDV, ddI†† 1.5 45 97 Asymptomatic HIV No Not tested
infection
1997** Large or hollow-bore ZDV, 3TC, IDV§§ 1.5 40 55 AIDS Yes No
needle
1998¶¶ Hollow-bore needle ZDV, 3TC, ddI, IDV 0.7 70 83 AIDS Yes Yes
1999*** Unknown sharp ddI, d4T, NVP††† 2.0 42 100 AIDS Yes Yes
2001§§§ Phlebotomy needle ZDV, 3TC, IDV¶¶¶ 1.6 24 ~90 AIDS Yes Yes
* ZDV = zidovudine; ddI = didanosine; 3TC = lamivudine; IDV = indinavir; d4T = stavudine; and NVP = nevirapine.
† By enzyme immunoassay for HIV-1 antibody and Western blot.
§ By genotypic or phenotypic resistance testing.
¶ Source: Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med 1997;102(Suppl 5B):52–5.
** Source: Lot F, Abiteboul D. Occupational infections with HIV in France among health-care personnel [French]. Bull Epi Hebdom 1999;18:69–70.
†† ZDV and ddI taken for 48 hours and then changed to ZDV alone.
§§ ZDV, 3TC, and IDV taken for 48 hours and then changed to d4T, 3TC, and IDV.
¶¶ Source: Perdue B, Wolde Rufael D, Mellors J, Quinn T, Margolick J. HIV-1 transmission by a needlestick injury despite rapid initiation of four-drug
postexposure prophylaxis [Abstract no 210]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL:
Foundation for Retrovirology and Human Health; 1999.
*** Source: Beltrami EM, Luo C-C, de la Torre N, Cardo DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure
prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345–8; CDC, unpublished data, 1999.
††† ZDV and 3TC taken for 1 dose and then changed to ddI, d4T, and NVP; ddI was discontinued after 3 days as a result of severe vomiting.
§§§ Source: Hawkins DA, Asboe D, Barlow K, Evans B. Seroconversion to HIV-1 following a needlestick injury despite combination post-exposure prophylaxis.
J Infect 2001;43:12–5.
¶¶¶ ZDV, 3TC, and IDV initially and then changed after first dose to d4T, ddI, and NVP; then ddI discontinued after 8 days; and d4T and NVP taken for 4 weeks.
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The worker was referred to a hospital where the regimen was
changed within 6 hours of the exposure to didanosine (ddI),
d4T, and NVP because of concerns regarding possible drug
resistance to certain or all of the components of the initial
PEP regimen. The exposed worker stopped ddI after 8 days
because of symptoms but continued to take d4T and NVP,
stopping at day 24 because of a generalized macular pruritic
rash and mild thrombocytopenia. Seroconversion was docu-
mented at 3 months. Sequencing of viruses from the source
and exposed worker demonstrated their close relatedness.
Virus from the worker demonstrated the same resistance pat-
terns as those in the source patient. In addition, the worker’s
virus had a mutation suggesting resistance to the NNRTI class
(38).
Empiric decisions regarding the presence of antiretroviral
drug resistance are often difficult because patients frequently
take more than one antiretroviral agent. Resistance should be
suspected in a source patient when clinical progression of dis-
ease or a persistently increasing viral load or decline in CD4+
T-cell count occurs despite therapy, or when no virologic
response to therapy occurs. However, resistance testing of the
source virus at the time of an exposure is impractical because
the results will not be available in time to influence the choice
of the initial PEP regimen. No data suggest that modification
of a PEP regimen after resistance testing results become avail-
able (usually 1–2 weeks) improves efficacy of PEP (41).
Antiretroviral Drugs During Pregnancy
Data regarding the potential effects of antiretroviral drugs
on the developing fetus or neonate are limited (3). Carcino-
genicity and mutagenicity are evident in certain in vitro screen-
ing tests for ZDV and all other FDA-licensed NRTIs. The
relevance of animal data to humans is unknown; however,
because teratogenic effects were reported among primates at
drug exposures similar to those representing human thera-
peutic exposure, pregnant women should not use efavirenz
(EFV). Indinavir (IDV) is associated with infrequent side
effects in adults (i.e., hyperbilirubinemia and renal stones)
that could be problematic for a newborn. Because the half-
life of IDV in adults is short, these concerns might be relevant
only if the drug is administered shortly before delivery. Other
concerns regarding use of PEP during pregnancy have been
raised by reports of mitochondrial dysfunction leading to neu-
rologic disease and death among uninfected children whose
mothers had taken antiretroviral drugs to prevent perinatal
HIV transmission and of fatal and nonfatal lactic acidosis in
pregnant women treated throughout gestation with a combi-
nation of d4T and ddI (3).
Management of Occupational Exposure
by Emergency Physicians
Although PHS guidelines for the management of occupa-
tional exposures to HIV were first published in 1985 (42),
HCP often are not familiar with these guidelines. Focus groups
conducted among emergency department (ED) physicians in
2002 indicated that of 71 participants, >95% had not read
the 2001 guidelines before being invited to participate (43).
All physicians participating in these focus groups had man-
aged occupational exposures to blood or body fluids. They
cited three challenges in exposure management most fre-
quently: evaluation of an unknown source patient or a source
patient who refused testing, inexperience in managing occu-
pational HIV exposures, and counseling of exposed workers
in busy EDs.
Occupational HIV Exposure
Management and PEP Use in U.S.
Hospitals
Analysis of NaSH data for June 1995–December 2004 pro-
vides information regarding the management of occupational
exposure to HIV in a convenience sample of 95 U.S. hospi-
tals. These data indicate improved adherence to PHS recom-
mendations concerning use of HIV PEP after occupational
exposures. A total of 28,010 exposures to blood and body
fluids were reported by these hospitals (CDC, unpublished
data, 2005). For all 25,510 exposures with known sources,
1,350 (5.3%) were to HIV-positive sources, 15,301 (60.0%)
to HIV-negative sources, and 8,859 (34.7%) to sources of
unknown HIV status. Of 1,350 HCP exposed to a known
HIV-positive source, 788 (58.4%) started PEP, and 317 (49%)
of 647 for whom follow-up information was available took
PEP for >21 days. The overall median duration of HIV PEP
after exposure to an HIV-positive source was 27 days, increas-
ing from 10 days in 1995 to 26.5 days in 2004; the overall
median duration of HIV PEP after exposure to an HIV-
negative source was 2 days, decreasing from 7.5 days in 1995
to 1 day in 2004. The use of rapid HIV tests for evaluation of
source patients has increased; during 1995–1997, none of 25
NaSH facilities used rapid HIV tests, whereas in 2004, a total
of 21 (84% ) did (CDC, unpublished data, 2005). Rapid HIV
tests could result in decreased use of PEP and spare personnel
both undue anxiety and adverse effects of antiretroviral PEP
(44–47). The annual median time to initiation of PEP was
consistent (2 hours). Of 1,350 HCP with exposures to HIV-
positive sources, 909 (67.1%) had at least one follow-up sero-
logic test recorded, but only 289 (31.8%) had tests recorded
at 4–6 months (CDC, unpublished data, 2005).
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In 1996, of 24 HCP taking PEP after exposure to HIV-
positive sources, 10 (42%) took a three-drug PEP regimen
compared with 30 (76.9%) of 39 in 2004 (CDC, unpub-
lished data, 2005). After 227 HIV exposures for which only a
two-drug PEP regimen was recommended (i.e., the exposure
was to mucous membranes or skin or was a superficial percu-
taneous injury and the source person did not have end-stage
AIDS or acute HIV illness), 104 (45.8%) HCP initiated a
three-drug HIV PEP regimen. The National Clinicians’ Post-
Exposure Prophylaxis Hotline (PEPline)† reports similar find-
ings. PEPline staff recommended changing or discontinuing
PEP regimens for 45 (38%) of 118 exposures involving source
patients with known viral load or CD4 cell count concerning
which they were consulted during April 2002–March 2003
(48; R. Goldschmidt, PEPline, personal communication,
2004). For 14 (11.9%) HCP, the recommendation was to
decrease the number of drugs in the PEP regimens; for 22
(18.7%) HCP, the recommendation was to increase the num-
ber of drugs; and for nine (7.6%), the recommendation was
to change the PEP regimen, keeping the same number of drugs.
Recommendations for the
Management of HCP Potentially
Exposed to HIV
Exposure prevention remains the primary strategy for
reducing occupational bloodborne pathogen infections. How-
ever, occupational exposures will continue to occur, and PEP
will remain an important element of exposure management.
HIV PEP
The recommendations provided in this report (Tables 1 and
2; Appendix) apply to situations in which HCP have been
exposed to a source person who either has or is considered
likely to have HIV infection. These recommendations are based
on the risk for HIV infection after different types of exposure
and on limited data regarding efficacy and toxicity of PEP. If
PEP is offered and taken and the source is later determined to
be HIV-negative, PEP should be discontinued. Although con-
cerns have been expressed regarding HIV-negative sources
being in the window period for seroconversion, no case of
transmission involving an exposure source during the win-
dow period has been reported in the United States (39). Rapid
HIV testing of source patients can facilitate making timely
decisions regarding use of HIV PEP after occupational expo-
sures to sources of unknown HIV status. Because the major-
ity of occupational HIV exposures do not result in transmission
of HIV, potential toxicity must be considered when prescrib-
ing PEP. Because of the complexity of selecting HIV PEP regi-
mens, when possible, these recommendations should be
implemented in consultation with persons having expertise
in antiretroviral therapy and HIV transmission. Reevaluation
of exposed HCP should be strongly encouraged within
72 hours postexposure, especially as additional information
about the exposure or source person becomes available.
Timing and Duration of PEP
PEP should be initiated as soon as possible, preferably within
hours rather than days of exposure. If a question exists con-
cerning which antiretroviral drugs to use, or whether to use a
basic or expanded regimen, the basic regimen should be started
immediately rather than delay PEP administration. The opti-
mal duration of PEP is unknown. Because 4 weeks of ZDV
appeared protective in occupational and animal studies, PEP
should be administered for 4 weeks, if tolerated (49–52).
Recommendations for the Selection
of Drugs for HIV PEP
The selection of a drug regimen for HIV PEP must balance
the risk for infection against the potential toxicities of the
agent(s) used. Because PEP is potentially toxic, its use is not
justified for exposures that pose a negligible risk for transmis-
sion (Tables 1 and 2). The initial HIV PEP regimens recom-
mended in these guidelines should be viewed as suggestions
that can be changed if additional information is obtained
concerning the source of the occupational exposure (e.g.,
possible treatment history or antiretroviral drug resistance) or
if expert consultation is provided. Given the complexity of
choosing and administering HIV PEP, whenever possible,
consultation with an infectious diseases consultant or another
physician who has experience with antiretroviral agents is rec-
ommended, but it should not delay timely initiation of PEP.
Consideration should be given to the comparative risk rep-
resented by the exposure and information regarding the expo-
sure source, including history of and response to antiretroviral
therapy based on clinical response, CD4+ T-cell counts, viral
load measurements, and current disease stage. When the source
person’s virus is known or suspected to be resistant to one or
more of the drugs considered for the PEP regimen, the
selection of drugs to which the source person’s virus is
unlikely to be resistant is recommended; expert consultation
is advised. If this information is not immediately available,
initiation of PEP, if indicated, should not be delayed; changes
† Administered by staff members from the University of California at San
Francisco and San Francisco General Hospital; supported by the Health
Resources and Services Administration Ryan White CARE Act and AIDS
Education and Training Centers, and by CDC.
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in the regimen can be made after PEP has started, as appro-
priate. For HCP who initiate PEP, re-evaluation of the
exposed person should occur within 72 hours postexposure,
especially if additional information about the exposure or
source person becomes available.
PHS continues to recommend stratification of HIV PEP
regimens based on the severity of exposure and other consid-
erations (e.g., concern for antiretroviral drug resistance in the
exposure source). The majority of HIV exposures will war-
rant a two-drug regimen, using two NRTIs or one NRTI and
one NtRTI (Tables 1 and 2; Appendix). Combinations that
can be considered for PEP include ZDV and 3TC or
emtricitabine (FTC); d4T and 3TC or FTC; and tenofovir
(TDF) and 3TC or FTC. In the previous PHS guidelines, a
combination of d4T and ddI was considered one of the first-
choice PEP regimens; however, this regimen is no longer rec-
ommended because of concerns about toxicity (especially
neuropathy and pancreatitis) and the availability of more
tolerable alternative regimens (3).
The addition of a third (or even a fourth) drug should be
considered for exposures that pose an increased risk for trans-
mission or that involve a source in whom antiretroviral drug
resistance is likely. The addition of a third drug for PEP after
a high-risk exposure is based on demonstrated effectiveness in
reducing viral burden in HIV-infected persons. However, no
definitive data exist that demonstrate increased efficacy of
three- compared with two-drug HIV PEP regimens. Previ-
ously, IDV, nelfinavir (NFV), EFV, or abacavir (ABC) were
recommended as first-choice agents for inclusion in an
expanded PEP regimen (3).
PHS now recommends that expanded PEP regimens be PI-
based. The PI preferred for use in expanded PEP regimens is
lopinavir/ritonavir (LPV/RTV). Other PIs acceptable for use
in expanded PEP regimens include atazanavir, fosamprenavir,
RTV-boosted IDV, RTV-boosted SQV, or NFV (Appendix).
Although side effects are common with NNRTIs, EFV may
be considered for expanded PEP regimens, especially when
resistance to PIs in the source person’s virus is known or sus-
pected. Caution is advised when EFV is used in women of
childbearing age because of the risk of teratogenicity.
Drugs that may be considered as alternatives to the expanded
regimens, with warnings about side effects and other adverse
events, are EFV or PIs as noted in the Appendix in combina-
tion with ddl and either 3TC or FTC. The fusion inhibitor
enfuvirtide (T20) has theoretic benefits for use in PEP
because its activity occurs before viral-host cell integration;
however, it is not recommended for routine HIV PEP
because of the mode of administration (subcutaneous injec-
tion twice daily). Furthermore, use of T20 has the potential for
production of anti-T20 antibodies that cross react with HIV
gp41. This could result in a false-positive, enzyme immunoas-
say (EIA) HIV antibody test among HIV-uninfected patients.
A confirmatory Western blot test would be expected to be
negative in such cases. T20 should only be used with expert
consultation.
Antiviral drugs not recommended for use as PEP, primarily
because of the higher risk for potentially serious or life-
threatening adverse events, include ABC, delavirdine, ddC,
and, as noted previously, the combination of ddI and d4T.
NVP should not be included in PEP regimens except with
expert consultation because of serious reported side effects,
including hepatotoxicty (with one instance of fulminant liver
failure requiring liver transplantation), rhabdomyolysis, and
hypersensitivity syndrome (53–55).
Because of the complexity of selection of HIV PEP regi-
mens, consultation with persons having expertise in
antiretroviral therapy and HIV transmission is strongly rec-
ommended. Certain institutions have required consultation
with a hospital epidemiologist or infectious diseases consult-
ant when HIV PEP use is under consideration. This can be
especially important in management of a pregnant or
breastfeeding worker or a worker who has been exposed to a
heavily treatment-experienced source (Box 1).
Resources for consultation are available from the following
sources:
• PEPline at http://www.ucsf.edu/hivcntr/Hotlines/
PEPline; telephone 888-448-4911;
• HIV Antiretroviral Pregnancy Registry at http://
www.apregistry.com/index.htm; Address: Research Park,
1011 Ashes Drive, Wilmington, NC 28405. Telephone:
800-258-4263; Fax: 800-800-1052; E-mail:
registry@nc.crl.com;
• FDA (for reporting unusual or severe toxicity to
antiretroviral agents) at http://www.fda.gov/medwatch;
telephone: 800-332-1088; address: MedWatch, HF-2,
Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857;
• CDC (for reporting HIV infections in HCP and failures
of PEP) at telephone 800-893-0485; and
• HIV/AIDS Treatment Information Service at http://
aidsinfo.nih.gov.
Follow-Up of Exposed HCP
Postexposure Testing
HCP with occupational exposure to HIV should receive
follow-up counseling, postexposure testing, and medical evalu-
ation regardless of whether they receive PEP. HIV-antibody
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testing by enzyme immunoassay should be used to monitor
HCP for seroconversion for >6 months after occupational HIV
exposure. After baseline testing at the time of exposure, fol-
low-up testing could be performed at 6 weeks, 12 weeks, and
6 months after exposure. Extended HIV follow-up (e.g., for
12 months) is recommended for HCP who become infected
with HCV after exposure to a source coinfected with HIV
and HCV. Whether extended follow-up is indicated in other
BOX 1. Situations for which expert consultation* for HIV
postexposure prophylaxis (PEP) is advised
• Delayed (i.e., later than 24–36 hours) exposure report
— Interval after which lack of benefit from PEP
undefined
• Unknown source (e.g., needle in sharps disposal
container or laundry)
— Use of PEP to be decided on a case-by-case basis
— Consider severity of exposure and epidemiologic
likelihood of HIV exposure
— Do not test needles or other sharp instruments for
HIV
• Known or suspected pregnancy in the exposed person
— Use of optimal PEP regimens not precluded
— PEP not denied solely on basis of pregnancy
• Breastfeeding in the exposed person
— Use of optimal PEP regimens not precluded
— PEP not denied solely on basis of breastfeeding
• Resistance of the source virus to antiretroviral agents
— Influence of drug resistance on transmission risk
unknown
— If source person’s virus is known or suspected to be
resistant to one or more of the drugs considered for
PEP, selection of drugs to which the source person’s
virus is unlikely to be resistant recommended
— Resistance testing of the source person’s virus at the
time of the exposure not recommended
— Initiation of PEP not to be delayed while awaiting
any results of resistance testing
• Toxicity of the initial PEP regimen
— Adverse symptoms (e.g., nausea and diarrhea)
common with PEP
— Symptoms often manageable without changing PEP
regimen by prescribing antimotility or antiemetic
agents
— In other situations, modifying the dose interval (i.e.,
taking drugs after meals or administering a lower
dose of drug more frequently throughout the day,
as recommended by the manufacturer) might help
alleviate symptoms when they occur
* Either with local experts or by contacting the National Clinicians’ Post-
Exposure Prophylaxis Hotline (PEPline), telephone 888-448-4911.
circumstances (e.g., exposure to a source co-infected with HIV
and HCV in the absence of HCV seroconversion or for ex-
posed persons with a medical history suggesting an impaired
ability to mount an antibody response to acute infection) is
unclear. Although rare instances of delayed HIV
seroconversion have been reported (56,57), the infrequency
of this occurrence does not warrant adding to exposed per-
sons’ anxiety by routinely extending the duration of
postexposure follow-up. However, this should not preclude a
decision to extend follow-up in a particular situation based
on the clinical judgment of the exposed person’s health-care
provider. The routine use of direct virus assays (e.g., HIV p24
antigen EIA or tests for HIV ribonucleic acid) to detect infec-
tion among exposed HCP usually is not recommended (58).
Despite the ability of direct virus assays to detect HIV infec-
tion a few days earlier than EIA, the infrequency of occupa-
tional seroconversion and increased costs of these tests do not
warrant their routine use in this setting. In addition, the rela-
tively high rate of false-positive results of these tests in this
setting could lead to unnecessary anxiety or treatment (59,60).
Nevertheless, HIV testing should be performed on any
exposed person who has an illness compatible with an acute
retroviral syndrome, regardless of the interval since exposure.
A person in whom HIV infection is identified should be
referred for medical management to a specialist with expertise
in HIV treatment and counseling. Health-care providers car-
ing for persons with occupationally acquired HIV infection
can report these cases to CDC at telephone 800-893-0485 or
to their state health departments.
Monitoring and Management of PEP Toxicity
If PEP is used, HCP should be monitored for drug toxicity
by testing at baseline and again 2 weeks after starting PEP.
The scope of testing should be based on medical conditions
in the exposed person and the toxicity of drugs included in
the PEP regimen. Minimally, laboratory monitoring for tox-
icity should include a complete blood count and renal and
hepatic function tests. Monitoring for evidence of hypergly-
cemia should be included for HCP whose regimens include
any PI; if the exposed person is receiving IDV, monitoring for
crystalluria, hematuria, hemolytic anemia, and hepatitis also
should be included. If toxicity is noted, modification of the
regimen should be considered after expert consultation;
further diagnostic studies might be indicated.
Exposed HCP who choose to take PEP should be advised
of the importance of completing the prescribed regimen.
Information should be provided about potential drug
interactions and drugs that should not be taken with PEP,
side effects of prescribed drugs, measures to minimize side
effects, and methods of clinical monitoring for toxicity
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during the follow-up period. HCP should be advised that
evaluation of certain symptoms (e.g., rash, fever, back or ab-
dominal pain, pain on urination or blood in the urine, or
symptoms of hyperglycemia (e.g., increased thirst or frequent
urination) should not be delayed.
HCP often fail to complete the recommended regimen
often because they experience side effects (e.g., nausea or di-
arrhea). These symptoms often can be managed with
antimotility and antiemetic agents or other medications that
target specific symptoms without changing the regimen. In
other situations, modifying the dose interval (i.e., administer-
ing a lower dose of drug more frequently throughout the day,
as recommended by the manufacturer) might facilitate
adherence to the regimen. Serious adverse events§ should be
reported to FDA’s MedWatch program.
Although recommendations for follow-up testing, moni-
toring, and counseling of exposed HCP are unchanged from
those published previously (3), greater emphasis is needed on
improving follow-up care provided to exposed HCP (Box 2).
This might result in increased adherence to HIV PEP regi-
mens, better management of associated symptoms with ancil-
lary medications or regimen changes, improved detection of
serious adverse effects, and serologic testing among a larger
proportion of exposed personnel to determine if infection is
transmitted after occupational exposures. Closer follow-up
should in turn reassure HCP who become anxious after these
events (61,62). The psychologic impact on HCP of
needlesticks or exposure to blood or body fluid should not be
underestimated. Providing HCP with psychologic counseling
should be an essential component of the management and
care of exposed HCP.
Reevaluation and Updating of HIV PEP
Guidelines
As new antiretroviral agents for treatment of HIV infection
and additional information concerning early HIV infection
and prevention of HIV transmission become available, the
PHS Interagency Working Group will assess the need to
update these guidelines. Updates will be published periodi-
cally as appropriate.
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APPENDIX
Basic and Expanded HIV Postexposure Prophylaxis Regimens
BASIC REGIMEN
• Zidovudine (Retrovir™; ZDV; AZT) + lamivudine
(Epivir®; 3TC); available as Combivir™
Preferred dosing
— ZDV: 300 mg twice daily or 200 mg three times daily,
with food; total: 600 mg daily
— 3TC: 300 mg once daily or 150 mg twice daily
— Combivir: one tablet twice daily
Dosage forms
— ZDV: 100 mg capsule, 300 mg tablet
— 3TC: 150 or 300 mg tablet
— Combivir: tablet, 300 mg ZDV + 150 mg 3TC
Advantages
— ZDV associated with decreased risk for HIV
transmission
— ZDV used more often than other drugs for PEP for
health-care personnel (HCP)
— Serious toxicity rare when used for PEP
— Side effects predictable and manageable with
antimotility and antiemetic agents
— Can be used by pregnant HCP
— Can be given as a single tablet (COMBIVIR™) twice
daily
Disadvantages
— Side effects (especially nausea and fatigue) common
and might result in low adherence
— Source-patient virus resistance to this regimen possible
— Potential for delayed toxicity (oncogenic/teratogenic)
unknown
• Zidovudine (Retrovir®; ZDV; AZT) + emtrictabine
(Emtriva™; FTC)
Preferred dosing
— ZDV:  300 mg twice daily or 200 mg three times
daily, with food; total: 600 mg/day, in 2–3 divided
doses
— FTC: 200 mg (one capsule) once daily
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• Tenofovir DF (Viread®; TDF) + emtricitabine
(Emtriva™; FTC); available as Truvada™
Preferred dosing
— TDF: 300 mg once daily
— FTC: 200 mg once daily
— As Truvada™: one tablet daily
Dosage forms
— TDF: 300 mg tablet
— FTC: see FTC
— Truvada™ (TDF 300 mg plus FTC 200 mg)
Advantages
— FTC: see above
— TDF
o Convenient dosing (single pill once daily)





o Same class warnings as NRTIs
o Drug interactions
o Increased TDF concentrations among persons tak-
ing atazanavir and lopinavir/ritonavir; need to
monitor patients for TDF-associated toxicities
o Preferred dosing of atazanavir if used with TDF:
300 mg + ritonavir 100 mg once daily + TDF 300
mg once daily
ALTERNATE BASIC REGIMENS
• Lamivudine (Epivir®; 3TC) + stavudine (Zerit®; d4T)
Preferred dosing
— 3TC: 300 mg once daily or 150 mg twice daily
— d4T: 40 mg twice daily (can use lower doses of
20–30 mg twice daily if toxicity occurs; equally
effective but less toxic among HIV-infected patients
with peripheral neuropathy); 30 mg twice daily if
body weight is <60 kg
Dosage forms
— 3TC: see above
— d4T: 15, 20, 30, and 40 mg tablet
Advantages
— 3TC: see above
— d4T: gastrointestinal (GI) side effects rare
Disadvantages
— Possibility that source-patient virus is resistant to this
regimen
— Potential for delayed toxicity (oncogenic/teratogenic)
unknown
Dosage forms
— ZDV: see above
— FTC: 200 mg capsule
FTC general comments
— Nucleoside analogue; same structure as 3TC, except
fluoride residue at position 5 on pyrimidine ring
— Same resistance and safety profile as 3TC
— No apparent advantage over 3TC; tolerability and
virologic response rates appear better than regimens
containing ddI + d4T
Advantages
— ZDV: see above.
— FTC
o Convenient (once daily)
o Well tolerated
o Long intracellular half-life (~40 hours)
Disadvantages
— ZDV: see above.
— FTC
o Rash perhaps more frequent than with 3TC
o No long-term experience with this drug
o Cross resistance to 3TC
o Hyperpigimentation among non-Caucasians with
long-term use: 3%
• Tenofovir DF (Viread®; TDF) + lamivudine (Epivir®;
3TC)
Preferred dosing
— TDF: 300 mg once daily
— 3TC: 300 mg once daily or 150 mg twice daily
Dosage forms
— TDF: 300 mg tablet
— 3TC: see above
Advantages
— 3TC: see above
— TDF
o Convenient dosing (single pill once daily)





o Same class warnings as nucleoside reverse
transcriptase inhibitors (NRTIs)
o Drug interactions
o Increased TDF concentrations among persons
taking atazanavir and lopinavir/ritonavir; need to
monitor patients for TDF-associated toxicities
— Preferred dosage of atazanavir if used with TDF: 300
mg + ritonavir 100 mg once daily + TDF 300 mg
once daily
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• Emtricitabine (Emtriva™; FTC) + stavudine (Zerit®;
d4T)
Preferrred dosing
— FTC: 200 mg daily
— d4T: 40 mg twice daily (can use lower doses of 20–30
mg twice daily if toxicity occurs; equally effective but
less toxic among HIV-infected patients who devel-
oped peripheral neuropathy); if body weight is <60 kg,
30 mg twice daily
Dosage forms
— FTC: see above
— d4T: see above
Advantages
— 3TC and FTC: see above; d4T’s GI side effects rare
Disadvantages
— Potential that source-patient virus is resistant to this
regimen
— Unknown potential for delayed toxicity (oncogenic/
teratogenic) unknown
• Lamivudine (Epivir®; 3TC) + didanosine (Videx®;
ddI)
Preferred dosing
— 3TC: 300 mg once daily or 150 mg twice daily
— ddI: Videx® chewable/dispersible buffered tablets can
be administered on an empty stomach as either 200
mg twice daily or 400 mg once daily. Patients must
take at least two of the appropriate strength tablets at
each dose to provide adequate buffering and prevent
gastric acid degradation of ddI. Because of the need
for adequate buffering, the 200-mg strength tablet
should be used only as a component of a once-daily
regimen. The dose is either 200 mg twice daily or
400 mg once daily for patients weighing >60 kg and
125 mg twice daily or 250 mg once daily for patients
weighing >60 kg.
Dosage forms
— 3TC: 150 or 300 mg tablets
— ddI: 25, 50, 100, 150, or 200 mg buffered white tablets
Advantages
— ddI: once daily dosing option
— 3TC: see above
Disadvantages
— Tolerability: diarrhea more common with buffered
preparation than with enteric-coated preparation
— Associated with toxicity: peripheral neuropathy, pan-
creatitis, and lactic acidosis
— Must be taken on empty stomach except with TDF
— Drug interactions
— 3TC: see above
• Emtricitabine (Emtriva™; FTC) + didanosine (Videx®;
ddI)
Preferred dosing
— FTC: 200 mg once daily
— ddI: see above
Dosage forms
— ddI: see above
— FTC: see above
Advantages
— ddI: see above
— FTC: see above
Disadvantages
— Tolerability: diarrhea more common with buffered
than with enteric-coated preparation
— Associated with toxicity: peripheral neuropathy,
pancreatitis, and lactic acidosis
— Must be taken on empty stomach except with TDF
— Drug interactions
— FTC: see above
PREFERRED EXPANDED REGIMEN
Basic regimen plus:
• Lopinavir/ritonavir (Kaletra®; LPV/RTV)
Preferred dosing
— LPV/RTV: 400/100 mg = 3 capsules twice daily with
food
Dosage form
— LPV/RTV: 133/33 mg capsules
Advantages
— Potent HIV protease inhibitor
— Generally well-tolerated
Disadvantages
— Potential for serious or life-threatening drug interac-
tions (see Table 4)
— Might accelerate clearance of certain drugs, includ-
ing oral contraceptives (requiring alternative or addi-
tional contraceptive measures for women taking these
drugs)
— Can cause severe hyperlipidemia, especially
hypertriglyceridemia
— GI (e.g., diarrhea) events common
ALTERNATE EXPANDED REGIMENS
Basic regimen plus one of the following:
• Atazanavir (Reyataz®; ATV) + ritonavir (Norvir®; RTV)
Preferred dosing
— ATV: 400 mg once daily, unless used in combination
with TDF, in which case ATV should be boosted with
RTV, preferred dosing of ATV 300 mg + RTV: 100
mg once daily
16 MMWR September 30, 2005
Dosage forms
— ATV: 100, 150, and 200 mg capsules
— RTV:  100 mg capsule
Advantages
— Potent HIV protease inhibitor
— Convenient dosing – once daily
— Generally well tolerated
Disadvantages
— Hyperbilirubinemia and jaundice common
— Potential for serious or life-threatening drug interac-
tions (see Table 4)
— Avoid coadministration with proton pump inhibitors
— Separate antacids and buffered medications by 2 hours
and H2-receptor antagonists by 12 hours to avoid
decreasing ATV levels
— Caution should be used with ATV and products
known to induce PR prolongation (e.g., diltiazem)
• Fosamprenavir (Lexiva®; FOSAPV) + ritonavir
(Norvir®; RTV)
Preferred dosing
— FOSAPV: 1400 mg twice daily (without RTV)
— FOSAPV: 1400 mg once daily + RTV 200 mg once
daily
— FOSAPV: 700 mg twice daily + RTV 100 mg twice
daily
Dosage form
— FOSAPV: 700 mg tablets
— RTV: 100 mg capsule
Advantages
— Once daily dosing when given with ritonavir
Disadvantages
— Tolerability: GI side effects common
— Multiple drug interactions. Oral contraceptives
decrease fosamprenavir concentrations
— Incidence of rash in healthy volunteers, especially
when used with low doses of ritonavir. Differentiat-
ing between early drug-associated rash and acute
seroconversion can be difficult and cause extraordi-
nary concern for the exposed person
• Indinavir (Crixivan®; IDV) + ritonavir (Norvir®; RTV)
Preferred dosing
— IDV 800 mg + RTV 100 mg twice daily without
regard to food
Alternative dosing
— IDV: 800 mg every 8 hours, on an empty stomach
Dosage forms
— IDV:  200 mg, 333, and 400 mg capsule
— RTV:  100 mg capsule
Advantages
— Potent HIV inhibitor
Disadvantages
— Potential for serious or life-threatening drug interac-
tions (see Table 4)
— Serious toxicity (e.g., nephrolithiasis) possible;
consumption of 8 glasses of fluid/day required
— Hyperbilirubinemia common; must avoid this drug
during late pregnancy
— Requires acid for absorption and cannot be taken
simultaneously with ddI, chewable/dispersible buff-
ered tablet formulation (doses must be separated by
>1 hour)
• Saquinavir (Invirase®; SQV) + ritonavir (Norvir®;
RTV)
Preferred dosing
— SQV: 1,000 mg (given as Invirase) + RTV 100 mg,
twice daily
— SQV : five capsules twice daily + RTV: one capsule
twice daily
Dosage forms
— SQV (Invirase): 200 mg capsule
— RTV: 100 mg capsule
Advantages
— Generally well-tolerated, although GI events common
Disadvantages
— Potential for serious or life-threatening drug interac-
tions (see Table 4)
— Substantial pill burden
• Nelfinavir (Viracept®; NFV)
Preferred dosing
— NFV: 1,250 mg (2 x 625 mg or 5 x 250 mg tablets),
twice daily with a meal
Dosage forms




— Diarrhea or other GI events common
— Potential for serious and/or life-threatening drug
interactions (see Table 4)
• Efavirenz (Sustiva®; EFV)
Preferred dosing
— EFV: 600 mg daily, at bedtime
Dosage forms
— EFV: 50, 100, 200 capsules
— EFV: 600 mg tablet
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Advantages
— Does not require phosphorylation before activation
and might be active earlier than other antiretroviral
agents (a theoretic advantage of no demonstrated clini-
cal benefit)
— Once daily dosing
Disadvantages
— Drug associated with rash (early onset) that can be
severe and might rarely progress to Stevens-Johnson
syndrome
— Differentiating between early drug-associated rash and
acute seroconversion can be difficult and cause
extraordinary concern for the exposed person
— Central nervous system side effects (e.g., dizziness,
somnolence, insomnia, or abnormal dreaming) com-
mon; severe psychiatric symptoms possible (dosing
before bedtime might minimize these side effects)
— Teratogen; should not be used during pregnancy
— Potential for serious or life-threatening drug interac-
tions (see Table 5)
ANTIRETROVIRAL AGENTS GENERALLY NOT
RECOMMENDED FOR USE AS PEP
• Nevirapine (Viramune®; NVP)
Disadvantages
— Associated with severe hepatotoxicity (including at
least one case of liver failure requiring liver transplan-
tation in an exposed person taking PEP)
— Associated with rash (early onset) that can be severe
and progress to Stevens-Johnson syndrome
— Differentiating between early drug-associated rash and
acute seroconversion can be difficult and cause
extraordinary concern for the exposed person
— Drug interactions: can lower effectiveness of certain
antiretroviral agents and other commonly used
medicines
• Delavirdine (Rescriptor®; DLV)
Disadvantages
— Drug associated with rash (early onset) that can be
severe and progress to Stevens-Johnson syndrome
— Multiple drug interactions
• Abacavir (Ziagen®; ABC)
Disadvantages
— Severe hypersensitivity reactions can occur, usually
within the first 6 weeks
— Differentiating between early drug-associated rash/
hypersensitivity and acute seroconversion can be
difficult
• Zalcitabine (Hivid®; ddC)
Disadvantages
— Three times a day dosing
— Tolerability
— Weakest antiretroviral agent
ANTIRETROVIRAL AGENT FOR USE AS PEP ONLY
WITH EXPERT CONSULTATION
• Enfuvirtide (Fuzeon™; T20)
Preferred dosing
— T20: 90 mg (1 ml) twice daily by subcutaneous
injection
Dosage forms
— T20: Single-dose vial, reconstituted to 90 mg/ml
Advantages
— New class
— Unique viral target; to block cell entry
— Prevalence of resistance low
Disadvantages
— Twice-daily injection
— Safety profile: local injection site reactions
— Never studied among antiretroviral-naïve or HIV-
negative patients
— False-positive EIA HIV antibody tests might result
from formation of anti-T20 antibodies that cross-re-
act with anti-gp41 antibodies
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Goal and Objectives
This report provides recommendations regarding clinical practice for managing occupational exposures to HIV in health-care settings, including appropriate use of
HIV postexposure prophylaxis (PEP). The goal of this report is to provide recommendations for guiding clinical practice in managing PEP for health-care personnel
(HCP) with occupational exposure to HIV. Upon completion of this educational activity, the reader should be able to a) describe occupational exposures for which
exposure management is appropriate; b) describe the appropriate selection of HIV PEP; c) describe the appropriate use of HIV PEP; d) describe the follow-up
evaluation of exposed HCP; e) describe the follow-up counseling of exposed HCP; and f) list situations for which expert consultation in the management of
occupational exposures is recommended.
To receive continuing education credit, please answer all of the following questions.
1. Contact with which body fluid(s) poses a risk for HIV transmission in





E. A and D.
F. B and C.
2. What is the recommended duration of HIV PEP for occupational






3. What is the recommended time to initiation of HIV PEP after
exposure when PEP is indicated? (Choose the one correct answer.)
A. 2 days.
B. 24–48 hours.
C. As soon as possible (preferably within hours).
4. Follow-up after occupational exposures to HIV should include which
of the following? (Choose the one correct answer.)
A. Serologic follow-up for HIV infection.
B. Monitoring for adverse effects of HIV postexposure prophylaxis if taken.
C. Monitoring for acute seroconversion illness.
D. Counseling on adherence with HIV PEP and the emotional stress of
dealing with exposures.
E. All of the above.
5. The potential for interactions with other medications is greatest for
which of the antiretroviral drug classes recommended for HIV
postexposure prophylaxis? (Choose the one correct answer.)
A. Reverse transcriptase inhibitors (nucleoside analogues).
B. Nonnucleoside reverse transcriptase inhibitors.
C. Protease inhibitors.
D. A and B.
E. B and C.
F. A and C.
6. Which antiretrovirals are not currently recommended for use by





7. Resistance testing of the source-patient after an exposure should




8. Adverse effects of antiretroviral HIV postexposure prophylaxis are
uncommonly reported by HCP.
A. True.
B. False.
9. Which types of exposure pose a risk for HIV transmission in health-
care settings? (Indicate all that apply.)
A. Intact skin exposure to blood.
B. Mucous membrane splash of urine.
C. Needlestick injury after phlebotomy.
D. Splash of blood on abraded skin.
E. C and D.
F. A and B.
10. A 12-month serologic follow-up after an occupational exposure to
HIV is recommended in which situation(s)? (Indicate all that apply.)
A. Any percutaneous exposure to an HIV-infected source.
B. If the exposed worker takes HIV postexposure prophylaxis.
C. If the exposure source is coinfected with HIV and HCV and becomes
HCV-infected.
D. None of the above.






12. I plan to use these recommendations as the basis for …(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Overall, the length of the journal article was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
14. After reading this report, I am confident I can describe occupational


































































































































































































































































































































































































































































































































































































































































































































































































































































































































15. After reading this report, I am confident I can describe the appropriate






16. After reading this report, I am confident I can describe the appropriate






17. After reading this report, I am confident I can describe the follow-up






18. After reading this report, I am confident I can describe the follow-up






19. After reading this report, I am confident I can list situations for which














21. The instructional strategies used in this report (text, tables, boxes, and
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Correct answers for questions 1–10.
1. E; 2. D; 3. C; 4. E; 5. E; 6. A; 7. B; 8. B; 9. E; 10. C


















26. The availability of continuing education credit influenced my












28. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
29. How did you learn about the continuing education activity?
A. Internet.
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